How to Get Repatha (Evolocumab) in Hawaii

What Repatha Is and Why It Gets Prescribed

Evolocumab (Repatha) is a fully human monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more receptors active, so the liver clears more LDL-C from the bloodstream. The FDA approved it in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond diet and maximally tolerated statin therapy [1].

The FOURIER trial (N=27,564) published in the New England Journal of Medicine in 2017 is the landmark outcomes study. Patients on a background of high-intensity statin therapy who received evolocumab 140 mg every 2 weeks or 420 mg monthly achieved a 59% reduction in LDL-C from baseline (median LDL-C fell from 92 mg/dL to 30 mg/dL) and a 15% relative risk reduction in the primary composite endpoint of cardiovascular death, MI, stroke, coronary revascularization, or unstable angina over a median follow-up of 2.2 years (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) [2]. That 15% relative reduction translated to a 1.5 percentage-point absolute risk reduction, with the benefit widening over time.

The American College of Cardiology and American Heart Association 2018 Cholesterol Guideline states: "In patients with very high-risk ASCVD, if the LDL-C level remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable" [3]. That clinical threshold is the single most cited prior-authorization trigger in commercial plans.

Homozygous FH patients (HoFH) received an additional approval pathway in 2017. In the TESLA Part B trial (N=49), evolocumab 420 mg monthly on top of other lipid-lowering therapy reduced LDL-C by 30.9% vs. placebo (P<0.0001) [4]. HoFH is rare but severe, and patients in Hawaii with this diagnosis may qualify for an expedited prior-authorization review under medical necessity clauses.

Who Can Prescribe Repatha in Hawaii

Any licensed prescriber in Hawaii with DEA registration and state licensure can write a Repatha prescription. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Hawaii grants NPs full practice authority under Hawaii Revised Statutes Chapter 457, meaning an NP practicing independently, including through a telehealth platform, can initiate a PCSK9 inhibitor prescription without physician co-signature [5].

PAs in Hawaii require a supervising physician relationship, but supervision may be remote. A PA working through a telehealth service that has a supervising MD licensed in Hawaii can legally prescribe evolocumab to a Hawaii patient.

The practical implication: you are not limited to finding a local cardiologist. A telehealth visit with a board-certified clinician licensed in Hawaii is a legally valid path to a Repatha prescription, provided the clinical criteria are met. Several national telehealth platforms now hold Hawaii licensure specifically for cardiovascular and lipid management services.

How to Get a Repatha Prescription in Hawaii: Step by Step

Getting a Repatha prescription follows a predictable sequence regardless of whether you see a doctor in person or use telehealth. Each step has a distinct purpose and timeline.

Step 1. Establish the clinical indication. Your provider must document either (a) a diagnosis of HeFH or HoFH confirmed by genetic testing or clinical criteria (Dutch Lipid Clinic Network score, Simon Broome criteria), or (b) established ASCVD defined as prior MI, stroke, peripheral arterial disease, or coronary revascularization. This documentation forms the medical-necessity backbone of your prior-authorization request [3].

Step 2. Show maximally tolerated statin therapy. Every major insurer in Hawaii requires evidence of a high-intensity statin trial, typically atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg, before approving a PCSK9 inhibitor. If you are statin-intolerant, you need documented evidence of intolerance across at least two statins, with the adverse event recorded in your medical record. The ACC/AHA guideline specifically defines statin intolerance as "inability to tolerate 2 or more statins" as a reason to consider non-statin therapy [3].

Step 3. Order the required labs. See the dedicated lab section below.

Step 4. Your provider submits prior authorization. This is the most time-consuming step. Expect 3 to 15 business days for commercial plan review. Amgen's reimbursement-support service, Repatha by Amgen, offers a PA submission assistance program that can cut administrative time for your provider's office [6].

Step 5. Prescription routes to a specialty pharmacy. Repatha is not stocked at most retail Hawaii pharmacies. It ships cold from specialty pharmacies. Common networks include CVS Specialty and Accredo. Amgen Connect can direct you to a specialty pharmacy contracted with your plan.

Step 6. First injection and training. Repatha is self-administered subcutaneously. The Pushtronex on-body infusor (420 mg/3.5 mL) is used once monthly; the SureClick autoinjector (140 mg/mL) is used every two weeks. Your pharmacy or provider's office provides injection training.

What Labs Are Needed Before Repatha in Hawaii

Four lab tests cover the baseline requirements that nearly every Hawaii insurer and treating clinician will want before initiating evolocumab.

Fasting lipid panel. This establishes your baseline LDL-C. Most prior-authorization forms require a documented LDL-C of 70 mg/dL or greater (or 100 mg/dL or greater for primary prevention FH) despite maximally tolerated therapy. Your lipid panel must be dated within 3 to 6 months, depending on plan requirements.

Calculated or direct LDL-C. If your triglycerides exceed 400 mg/dL, the Friedewald equation is unreliable. Request a direct LDL-C measurement in that case. The AHA notes that very high triglycerides invalidate Friedewald-derived LDL-C, which can cause PA denials if the submitted value appears spuriously low [7].

Hepatic function panel (AST, ALT, total bilirubin). Statins can raise liver enzymes, and some plans require a hepatic panel to confirm the patient is on background statin therapy and to rule out hepatic contraindications before adding a biologic. Evolocumab itself carries no hepatotoxicity signal in FOURIER, but the panel is standard pre-authorization documentation [2].

TSH (thyroid-stimulating hormone). Hypothyroidism causes secondary hypercholesterolemia. If your LDL-C is severely elevated and your TSH has not been checked in the past 12 months, many Hawaii providers and lipid specialists will order it to confirm the hypercholesterolemia is not primarily thyroid-driven before committing to a PCSK9 inhibitor [8].

Genetic testing for FH (LDL receptor, apolipoprotein B, PCSK9 gene panel) is not universally required for PA but can accelerate approval, particularly for HoFH. The American College of Medical Genetics recommends cascade genetic testing for first-degree relatives of patients with confirmed FH [9].

Telehealth Prescribing of Repatha in Hawaii

Hawaii permits telehealth prescribing of non-controlled prescription drugs, including biologics like evolocumab, under the Hawaii Telehealth Act (HRS §453-1.3). A clinician licensed in Hawaii who conducts a synchronous audio-video visit satisfies the prescriber-patient relationship requirement without a prior in-person visit [5].

The practical workflow for a telehealth Repatha visit in Hawaii runs as follows. You upload recent lab results (lipid panel dated within 6 months), a list of current medications documenting statin use, and any prior cardiology or PCP notes confirming your ASCVD or FH diagnosis. The telehealth clinician reviews these asynchronously before your live video appointment. During the appointment, they confirm clinical criteria, discuss injection technique, and, if prescribing is appropriate, send the PA request to your insurer electronically. Approval timelines are identical to in-person visits because the bottleneck is insurer review, not the clinical encounter itself.

One limitation specific to telehealth: some Hawaii commercial plans require the ordering provider to hold a Hawaiian license and to be credentialed as a specialist (cardiologist or endocrinologist) for PCSK9 inhibitor PA approval. If a general-practice telehealth NP submits the PA, the plan may request a specialist note. Checking your plan's specialty requirement before booking a telehealth visit saves time.

Prior Authorization Requirements in Hawaii

Prior authorization is required by virtually all commercial plans in Hawaii for Repatha. Hawaii Medicaid (Med-QUEST) does not cover evolocumab as of mid-2025, so Medicaid beneficiaries must access the drug through Amgen's patient-support programs or seek enrollment in a clinical trial.

A standard commercial PA submission in Hawaii requires:

1. Diagnosis code (ICD-10: E78.01 for HeFH, E78.02 for HoFH, I25.10 for chronic ischemic heart disease with ASCVD).
2. Documentation of LDL-C on maximally tolerated statin plus ezetimibe.
3. Records showing a trial of at least one high-intensity statin at the highest tolerated dose, or documentation of statin intolerance across two statins.
4. Most recent lipid panel result with date.
5. Letter of medical necessity from the prescribing provider.

The ACC/AHA 2022 Prevention Guideline update, published in the Journal of the American College of Cardiology, notes that PCSK9 inhibitors are cost-effective at a threshold of $150,000 per quality-adjusted life year when the drug list price falls below approximately $5,500 per year [10]. This cost-effectiveness argument, included in a PA appeal letter, has been cited by physicians as useful when a first PA is denied on cost grounds.

Initial PA approvals are commonly granted for 12 months and require annual re-authorization with repeat lipid documentation showing response. Most plans define adequate response as an LDL-C reduction of at least 30 to 50% from baseline or an achieved LDL-C below 70 mg/dL.

Pharmacy Access and Shipping to Hawaii

Repatha requires cold-chain shipping (2°C to 8°C). Hawaii's geographic isolation adds shipping complexity, but specialty pharmacy networks have established reliable routes to all major Hawaiian islands. CVS Specialty, Accredo (Express Scripts), and Walgreens Specialty Pharmacy all list Hawaii as a covered shipping destination.

Shipping time from continental U.S. specialty pharmacy fulfillment centers to Hawaii addresses runs 5 to 10 business days under standard cold-chain shipping. Expedited 2-day air options exist but must be requested explicitly. Amgen's Repatha by Amgen patient-support line (1-844-REPATHA) can assist in identifying the specialty pharmacy contracted with your specific insurance plan [6].

Retail pharmacies in Hawaii (Longs Drugs/CVS, Walmart Pharmacy, Safeway Pharmacy) do not routinely stock evolocumab. Attempting to fill a Repatha prescription at a retail pharmacy typically results in a "drug not stocked" response and a delay while the pharmacy attempts a special order. Routing the prescription directly to a specialty pharmacy is faster.

503A compounding pharmacies in Hawaii are licensed to compound drugs under state pharmacy board oversight, but evolocumab is a biologically complex monoclonal antibody produced through mammalian cell culture. 503A compounders cannot replicate this manufacturing process. No FDA-approved compounded version of evolocumab exists. Patients who encounter offers of "compounded evolocumab" at lower cost should treat these offers with significant caution, as no compounded PCSK9 inhibitor has undergone the pharmacokinetic validation required by the FDA [1].

Cost, Insurance, and Patient Assistance Programs

Repatha's U.S. list price is approximately $5,850 per year following Amgen's 2019 price reduction from approximately $14,100. Despite this reduction, prior authorization remains the norm because payers continue to require clinical-criteria verification [6].

Commercial insurance. Most Hawaii commercial plans (HMSA, Kaiser Permanente Hawaii, Ohana Health Plan commercial products, University Health Alliance) cover Repatha with PA for approved indications. Copays with Amgen's copay card can be reduced to as low as $5 per month for eligible commercially insured patients.

Hawaii Medicaid (Med-QUEST). Evolocumab is not on the Med-QUEST preferred drug list as of 2025. Medicaid beneficiaries may apply for Amgen's patient-assistance program, which provides Repatha at no cost to qualifying uninsured or underinsured patients with household income at or below 400% of the federal poverty level [6].

Medicare Part D. Coverage varies by plan. Under the Inflation Reduction Act's Part D redesign effective 2025, out-of-pocket catastrophic costs are capped, which may meaningfully reduce net cost for Medicare patients who reach the catastrophic threshold.

The FOURIER-OLE (open-label extension) data published in Circulation showed that patients who remained on evolocumab for up to 8.4 years maintained LDL-C reductions with no new safety signals, supporting long-term use in patients who achieve insurance coverage [11].

Transferring an Existing Repatha Prescription to Hawaii

If you are relocating to Hawaii with an active Repatha prescription, the process involves three tasks.

First, confirm your current prescriber is willing to continue managing your care remotely or that you have a Hawaii-licensed provider to take over. Repatha prescriptions in most states are written as 30-day or 90-day supplies routed through specialty pharmacies. Specialty pharmacies can update a shipping address to Hawaii mid-supply without requiring a new prescription in most cases, though some require updated state-specific prescription forms.

Second, notify your specialty pharmacy of the address change at least 10 business days before your next scheduled shipment to allow for cold-chain routing adjustments to Hawaii addresses.

Third, if you are switching insurance plans upon relocation, a new prior authorization will almost certainly be required under the new plan. Your prior authorization from your previous state does not transfer. Bring all prior lipid labs, statin trial documentation, and a current letter of medical necessity from your provider to accelerate the new PA submission.